Diastolic dysfunction of the left and right ventricles in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis

The frequency and risk factors for the development of diastolic function in patients with calcium pyrophosphate crystal deposition disease (CPPD) and osteoarthritis (OA) have not been studied.
The aim – to determine the frequency and to identify risk factors (RF) for the development of diastolic dysfunction (DD) of the left (LV) and right (RV) ventricles in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis.
Material and methods. 26 patients (18–65 years) each were included with CPРD and with knee OA, matched in age and gender, without cardiovascular disease (CVD), type 2 diabetes mellitus, rheumatic diseases. Traditional risk factors of CVD were assessed, echocardiography was performed.
Results. The frequency of DD in patients with CPРD and OA was quite high and almost did not differ in both groups: it was detected in 19 patients, of which 11 (42%) with CPРD and 8 (31%) with OA (p=0.39). Type 1 LV DD was detected in 10 (39%) patients with CPРD and in 8 (31%) with OA (p=0.11); type 1 RV DD – in 8 (31%) patients with CPРD and in 7 (27%) patients with OA (p=0.17); type 1 LV DD and RV DD – in 7 (27%) patients with both CPРD and with OA. DD types 2 and 3 were not detected in both groups. There were no differences in both groups in CV risk factors, except for the level of C-reactive protein (CRP) – it was higher in CPРD (p=0.03). In the CPРD group, mean values of LV E/E′ (p=0.02), LV DT (p=0.03), LV MI (p=0.04) were significantly higher than in patients with OA. On the contrary, in patients with OA, the following indicators: EDV (p=0.004), TVC (p=0.02) were higher.
There were direct correlations between diastolic function indices and the following factors in CPРD: LVL, PWLV and PTH level (r=0.7; p<0.005), LV E′ and PTH level (r=0.7; p<0.005); inverse correlations – the level of PTH and IS (r=–0.5; p<0.005), LV MI (r=–0.5; p<0.005), the level of vitamin D and VD DT (r=–0.6; p<0.005). Direct correlations in OA: the level of CRP and PVAdiast (r=0.6; p<0.005), and the level of sUA (r=0.7; p<0.005), the level of vitamin D and E/E′ LV (r=0.6; p<0.005).
Conclusion. A high prevalence of LV and RV DD was found in patients with CPРD and OA. The presence of DD in CPРD was associated with lower vitamin D levels, and in OA with a higher level of sUA and a lower level of PTH.

1. Fomin IV. Chronic heart failure in Russian Federation: What do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13 (In Russ.). doi: 15829/1560-4071-2016-8-7-13

2. Eliseev MS, Novikova AM, Zhelyabina OV, Gerasimova EV, Ilyinykh EV, Popkova TV, et al. Assessment of cardiovascular risk in patients with crystal-induced arthritides and rheumatoid arthritis by the ATP III and Reynolds Risk Score. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(5):512-519 (In Russ.). doi: 10.47360/1995-4484-2020-512-519

3. Turkiewicz A, Kiadaliri AA, Englund M. Cause-specific mortality in osteoarthritis of peripheral joints. Osteoarthritis Cartilage. 2019;27(6):848-854. doi: 10.1016/j.joca.2019.02.793

4. Eliseev MS, Cheremushkina EV, Zhelyabina OV, Chikina MN, Kapitonova AA, Novikova AA, et al. Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. Modern Rheumatology Journal. 2021; 15(6):76-83 (In Russ). doi: 10.14412/1996-7012-2021-6-76-83

5. Fomin IV, Belenkov YuN, Mareev VYu, Ageev FT, Badin YuV, Galyavich AS, et al. Prevalence of chronic heart failure in the European part of the Russian Federation: Data of the EPOCH-CHF. Zhurnal serdechnaya nedostatochnost. 2006;7(3):112-115 (In Russ.).

6. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507-515. doi: 10.1038/nrcardio.2014.83

7. Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch. 2014;466(6):1037-1053. doi: 10.1007/s00424-014-1480-8

8. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: Pathophysiology and therapeutic implications. J Am Coll Cardiol. 1993;22:318-325.

9. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373-394.

10. Tausche AK, Reuss-Borst M. Kristallarthritiden [Crystal arthropathies]. Dtsch Med Wochenschr. 2019;144(15):1055-1060. doi: 10.1055/a-0857-0916

11. Mobasheri A, Matta C, Zákány R, Musumeci G. Chondrosenescence: definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas. 2015;80(3):237-244. doi: 10.1016/j.maturitas.2014.12.003

12. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271. doi: 10.1016/j.jacc.2013.02.092

13. Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563-570. doi: 10.1136/ard.2010.139105

14. Nasonov EL (ed.). Rheumatology: Clinical recommendations. Moscow: GEOTAR-Media;2011 (In Russ.).

15. Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010;69(3):483-489. doi: 10.1136/ard.2009.113100

16. Lafitte S. Do we need new echocardiographic prognosticators for the management of heart failure patients? J Am Coll Cardiol. 2009;54(7):625-627. doi: 10.1016/j.jacc.2009.04.058

17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.; American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2):79-108. doi: 10.1016/j.euje.2005.12.014

18. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613-618. doi: 10.1161/01.cir.55.4.613

19. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083 (In Russ.). doi: 10.15829/1560-4071-2020-4083

20. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898-904. doi: 10.1001/jama.290.7.898

21. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935-2959. doi: 10.1016/j.jacc.2013.11.005

22. Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, et al. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020;27(Suppl 2):46-51. doi: 10.1177/2047487320961980

23. Eliseev MS, Zhelyabina OV, Chikina MN, Novikova AM. Cardiovascular risk factors in patients with calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(5):545-552 (In Russ.). doi: 10.14412/1995-4484-2019-545-552

24. Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):938-946. doi: 10.1177/2047487315610663

25. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: 10.1038/nature04516

26. Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ. How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int. 2009;29(3):229-238. doi: 10.1007/s00296-008-0710-9

27. Mathieu S, Couderc M, Tournadre A, Soubrier M. Cardiovascular profile in osteoarthritis: A meta-analysis of cardiovascular events and risk factors. Joint Bone Spine. 2019;86(6):679-684. doi: 10.1016/j.jbspin.2019.06.013

28. Fernandes GS, Valdes AM. Cardiovascular disease and osteoarthritis: Common pathways and patient outcomes. Eur J Clin Invest. 2015;45(4):405-414. doi: 10.1111/eci.12413

29. Lee JH, O’Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52(24):1949-1956. doi: 10.1016/j.jacc.2008.08.050

30. Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson K, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5(6):819-829. doi: 10.1161/CIRCOUTCOMES.112.967604

31. Gupta GK, Agrawal T, DelCore MG, Mohiuddin SM, Agrawal DK. Vitamin D deficiency induces cardiac hypertrophy and inflammation in epicardial adipose tissue in hypercholesterolemic swine. Exp Mol Pathol. 2012;93(1):82-90. doi: 10.1016/j.yexmp.2012.04.006

32. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-511. doi: 10.1161/CIRCULATIONAHA.107.706127

33. Pandit A, Mookadam F, Boddu S, Aryal Pandit A, Tandar A, Chaliki H, et al. Vitamin D levels and left ventricular diastolic function. Open Heart. 2014;1(1):e000011. doi: 10.1136/openhrt-2013-000011

34. Gandhi S, Myers RB. Can parathyroid hormone be used as a biomarker for heart failure? Heart Fail Rev. 2013;18(4):465-473. doi: 10.1007/s10741-012-9336-9

35. Romejko K, Rymarz A, Szamotulska K, Bartoszewicz Z, Niemczyk S. Serum osteoprotegerin is an independent marker of left ventricular hypertrophy, systolic and diastolic dysfunction of the left ventricle and the presence of pericardial fluid in chronic kidney disease patients. Nutrients. 2022;14(14):2893. doi: 10.3390/nu14142893

36. Georgiopoulos G, Tsioufis C, Kalos T, Magkas N, Roussos D, Chrysohoou C, et al. Serum uric acid is independently associated with diastolic dysfunction in apparently healthy subjects with essential hypertension. Curr Vasc Pharmacol. 2019;17(1): 99-106. doi: 10.2174/1570161116666171226124959